Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.

ABSTRACT:

Background and objective

Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) are uncommon in non-small cell lung cancer (NSCLC). These mutations are generally resistant to first-generation EGFR tyrosine kinase inhibitors, unlike common EGFR mutations, including exon 19 deletions or exon 21 L858R point mutation. The development of effective targeted therapies for NSCLC harboring EGFR ex20ins has been eagerly anticipated over the years. Recently, the therapeutic landscape of this subgroup of EGFR-mutant NSCLC patients has rapidly evolved due to the emergence of new drugs. In 2021, several novel agents, such as amivantamab and mobocertinib, have been approved by the US Food and Drug Administration for patients with advanced platinum-resistant NS

SUBMITTER: Watanabe N 

PROVIDER: S-EPMC9816854 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature